Cathepsin L silencing enhances arsenic trioxide mediated in vitro cytotoxicity and apoptosis in glioblastoma U87MG spheroids

Experimental Cell Research

Volumn 319, Issue 17, 2013, Pages 2637-2648

  Primon, Monika ^a,b   Huszthy, Peter C ^c   Motaln, Helena ^a   Talasila, Krishna M ^c   Torkar, Ana ^a   Bjerkvig, Rolf ^c   Lah Turnšek, Tamara ^a,d  

^a NATIONAL INSTITUTE OF BIOLOGY   (Slovenia)

^b BIA SEPARATIONS D O O   (Slovenia)

^c UNIVERSITY OF BERGEN   (Norway)

^d UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Apoptosis; Arsenic trioxide; Cathepsin L; Glioblastoma multiforme; Multicellular resistance effect; U87MG spheroids

Indexed keywords

ARSENIC TRIOXIDE; CASPASE 3; CASPASE 7; CATHEPSIN L; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; SHORT HAIRPIN RNA;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; ENZYME ACTIVITY; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LENTIVIRINAE; MONOLAYER CULTURE; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPHEROID CELL;

EID: 84885383143     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2013.08.011     Document Type: Article

References (53)

1. Westermark B. Glioblastoma-a moving target. Upsla J. Med. Sci. 2012, 117:251-256.
2. Mangiola A., Anile C., Pompucci A., Capone G., Rigante L., Bonis P.De, et al. Glioblastoma therapy: going beyond Hercules columns. Expert Rev. Neurother. 2010, 10:507-514.
3. Van Meir E.G., Hadjipanayis C.G., Norden A.D., Shu H., Wen P.Y., Olson J.J. Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J. Clin. 2010, 60:166-193.
4. Turk B., Turk D.S.A., Turk V. Protease signalling: the cutting edge. EMBO J. 2012, 31:1630-1643.
5. Lah T.T., Beatriz M., Alonso D., Van Noorden C.J.F. Antiprotease therapy in cancer: hot or not?. Expert Opin. Biol. Ther. 2006, 6:257-279.
6. Mohamed M.M., Sloane B.F. Cysteine cathepsins: multifunctional enzymes in cancer. Nat. Rev. Cancer 2006, 6:764-775.
7. Gocheva V., Zeng W., Ke D., Klimstra D., Reinheckel T., Peters C., et al. Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Gene Dev. 2006, 20:543-556.
8. Levicar N., Dewey R.a, Daley E., Bates T.E., Davies D., Kos J., et al. Selective suppression of cathepsin L by antisense cDNA impairs human brain tumor cell invasion in vitro and promotes apoptosis. Cancer Gene Ther. 2003, 10:141-151.
9. Strojnik T., Kavalar R., Trinkaus M., Lah T. Cathepsin L in glioma progression: comparison with cathepsin B. Cancer Detect Prev. 2005, 29:448-455.
10. Rao J.S. Molecular mechanisms of glioma invasiveness: the role of proteases. Nat. Rev. Cancer 2003, 3:489-501.
11. Goulet B., Baruch A., Moon N.-S., Poirier M., Sansregret L.L., Erickson A., et al. A cathepsin L isoform that is devoid of a signal peptide localizes to the nucleus in S phase and processes the CDP/Cux transcription factor. Mol. Cell. 2004, 14:207-219.
12. Nakagawa T., Cathepsin L Critical role in Ii degradation and CD4 T cell selection in the thymus. Science 1998, 280:450-453.
13. Stoka V., Turk B., Schendel S.L., Kim T.H., Cirman T., Snipas S.J., et al. Lysosomal protease pathways to apoptosis. Cleavage of bid, not pro-caspases, is the most likely route. J. Biol. Chem. 2001, 276:3149-3157.
14. Zheng X., Chu F., Chou P.M., Gallati C., Dier U., Mirkin B.L., et al. Cathepsin L inhibition suppresses drug resistance in vitro and in vivo: a putative mechanism. Am. J. Physiol. - Cell Physiol. 2009, 296:C65-C74.
15. Zajc I., Hreljac I., Lah T. Cathepsin L affects apoptosis of glioblastoma cells: a potential implication in the design of cancer therapeutics. Anticancer Res. 2006, 26:3357-3364.
16. Kenig S., Frangež R., Pucer A., Lah T. Inhibition of cathepsin L lowers the apoptotic threshold of glioblastoma cells by up-regulating p53 and transcription of caspases 3 and 7. Apoptosis 2011, 16:671-682.
17. Emadi A., Gore S.D. Arsenic trioxide - an old drug rediscovered. Blood Rev. 2010, 24:191-199.
18. Miller W.H., Schipper H.M., Lee J.S., Singer J., Waxman S. Mechanisms of action of arsenic trioxide. Cancer Res. 2002, 62:3893-3903.
19. Ai Z., Pan H., Suo T., Lv C., Wang Y., Tong S., et al. Arsenic oxide targets stem cell marker CD133/prominin-1 in gallbladder carcinoma. Cancer Lett. 2011, 310:181-187.
20. Liu L., Chen C., Gong W., Li Y., Edin M.L., Zeldin D.C., et al. Epoxyeicosatrienoic acids attenuate reactive oxygen species level, mitochondrial dysfunction, caspase activation and apoptosis in carcinoma cells treated with arsenic trioxide. J. Pharmacol. Exp. Ther. 2011, 339:451-463.
21. Shi Y., Hu B., Guo Y., Wang H., Xia J. Inhibitory mechanism on growth of MA-891 cells by arsenic trioxide. Zhongguo Zhong Yao Za Zhi 2012, 37:637-642.
22. Liu Z.-M., Tseng J.T., Hong D.-Y., Huang H.-S. Suppression of TG-interacting factor sensitizes arsenic trioxide-induced apoptosis in human hepatocellular carcinoma cells. Biochem. J. 2011, 438:349-358.
23. 3)-induced apoptosis in human glioblastoma cells. Cancer Sci. 2005, 96:825-833.
24. Pucer A., Castino R., Mirković B., Falnoga I., Slejkovec Z., Isidoro C., et al. Differential role of cathepsins B and L in autophagy-associated cell death induced by arsenic trioxide in U87 human glioblastoma cells. Biol. Chem. 2010, 391:519-531.
25. Ghaffari S.H., Bashash D., Dizaji M.Z., Ghavamzadeh A., Alimoghaddam K. Alteration in miRNA gene expression pattern in acute promyelocytic leukemia cell induced by arsenic trioxide: a possible mechanism to explain arsenic multi-target action. Tumour Biol. 2012, 33:157-172.
26. Lankelma J.M., Voorend D.M., Barwari T., Koetsveld J., Van der Spek A.H., Porto A.P.N.a De, et al. Cathepsin L, target in cancer treatment?. Life Sci. 2010, 86:225-233.
27. Elliott N.T., Yuan F.A.N. A review of three-dimensional in vitro tissue models for drug discovery and transport studies. J. Pharm. Sci. 2011, 100:59-74.
28. Torsvik A., Røsland G.V, Svendsen A., Molven A., Immervoll H., McCormack E., et al. Spontaneous malignant transformation of human mesenchymal stem cells reflects cross-contamination: putting the research field on track - letter. Cancer Res. 2010, 70:6393-6396.
29. Gole B., Durán Alonso M.B., Dolenc V., Lah T. Post-translational regulation of cathepsin B, but not of other cysteine cathepsins, contributes to increased glioblastoma cell invasiveness in vitro. Pathol. Oncol. Res. 2009, 15:711-723.
30. Kato D., Boatright K.M., Berger A.B., Nazif T., Blum G., Ryan C., et al. Activity-based probes that target diverse cysteine protease families. Nat. Chem. Biol. 2005, 1:33-38.
31. Goddard-Borger E.D., Stick R.V An efficient, inexpensive, and shelf-stable diazotransfer reagent: imidazole-1-sulfonyl azide hydrochloride. Org. Lett. 2007, 9:3797-3800.
32. Katritzky A.R., Singh S.K. Synthesis of C-carbamoyl-1,2,3-triazoles by microwave-induced 1,3-dipolar cycloaddition of organic azides to acetylenic amides. J. Org. Chem. 2002, 67:9077-9079.
33. N.Katunuma N. Structure-based development of specific inhibitors for individual cathepsins and their medical applications. Proc. Jpn. Acad. Ser. B 2011, 87:29-39.
34. Formolo C., Williams R., Gordish-Dressman H., MacDonald T., Lee N., Hathout Y. Secretome signature of invasive glioblastoma multiforme. J. Proteome Res. 2011, 10:3149-3159.
35. Felbor U., Dreier L., Bryant R.a, Ploegh H.L., Olsen B.R., Mothes W. Secreted cathepsin L generates endostatin from collagen XVIII. EMBO J. 2000, 19:1187-1194.
36. Alvarez S., Blanco A., Fresno M., Muñoz-Fernández M.Á. TNF-α contributes to caspase-3 independent apoptosis in neuroblastoma cells: role of NFAT. PloS One 2011, 6:e16100.
37. Grimm S.a, Marymont M., Chandler J.P., Muro K., Newman S.B., Levy R.M., et al. Phase I study of arsenic trioxide and temozolomide in combination with radiation therapy in patients with malignant gliomas. J. Neurooncol. 2012, 110:237-243.
38. Turk B. Targeting proteases: successes, failures and future prospects. Nat. Rev. Drug Discov. 2006, 5:785-799.
39. Wang Z., Rao D.D., Senzer N., Nemunaitis J. RNA interference and cancer therapy. Pharmaceut. Respir. 2011, 28:2983-2995.
40. Dufau I., Frongia C., Sicard F., Dedieu L., Cordelier P., Ausseil F., et al. Multicellular tumor spheroid model to evaluate spatio-temporal dynamics effect of chemotherapeutics: application to the gemcitabine/CHK1 inhibitor combination in pancreatic cancer. BMC Cancer 2012, 12:15.
41. Desoize B., Jardillier J. Multicellular resistance: a paradigm for clinical resistance?. Crit. Rev. Oncol.-Hematol. 2000, 36:193-207.
42. Oloumi A., Macphail S.H., Johnston P.J., Bana J.P., Olive P.L. Changes in subcellular distribution of topoisomerase II α correlate with etoposide resistance in multicell spheroids and xenograft tumors. Cancer Res. 2000, 60:5747-5753.
43. Thurber G.M., Wittrup K.D. Quantitative spatiotemporal analysis of antibody fragment diffusion and endocytic consumption in tumor spheroids. Cancer Res. 2010, 68:3334-3341.
44. Nederman T., Carlsson J. Penetration and binding of vinblastine and 5-fluorouracil in cellular spheroids. Cancer Chemother. Pharmacol. 1984, 13:131-135.
45. Han Y.H., Moon H.J., You B.R., Kim S.Z., Kim S.H., Park W.H. Effects of arsenic trioxide on cell death, reactive oxygen species and glutathione levels in different cell types. Int. J. Mol. Med. 2010, 25:121-128.
46. Park W.H., Kim S.H. Arsenic trioxide induces human pulmonary fibroblast cell death via the regulation of Bcl-2 family and caspase-8. Mol. Biol. Rep. 2012, 39:4311-4318.
47. Kim E.H., Yoon M.J., Kim S.U., Kwon T.K., Sohn S., Choi K.S. Arsenic trioxide sensitizes human glioma cells, but not normal astrocytes, to TRAIL-induced apoptosis via CCAAT/enhancer-binding protein homologous protein-dependent DR5 up-regulation. Cancer Res. 2008, 68:266-275.
48. Chui H.-W., Ho S.-Y., Guo H.-R., Wang Y.-J. Combination treatment with arsenic trioxide and irradiation enhances autophagic effects in U118-MG cells through increased mitotic arrest and regulation of PI3K/Akt anf ERK1/2 signaling pathways. Autophagy 2009, 5:472-483.
49. Kanzawa T., Zhang L., Xiao L., Germano I.M., Kondo Y., Kondo S. Arsenic trioxide induces autophagic cell death in malignant glioma cells by upregulation of mitochondrial cell death protein BNIP3. Oncogene 2005, 24:980-991.
50. Kim Y.-J., Chung J.-Y., Lee S.G., Kim J.Y., Park J.-E., Kim W.R., et al. Arsenic trioxide-induced apoptosis in TM4 Sertoli cells: the potential involvement of p21 expression and p53 phosphorylation. Toxicology 2011, 285:142-151.
51. Seehafer S., Pearce D. You say lipofuscin, we say ceroid: defining autofluorescent storage material. Neurobiol. Aging 2006, 27:576-588.
52. Degtyarev M., De Mazière A., Orr C., Lin J., Lee B.B., Tien J.Y., et al. Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents. J. Cell Biol. 2008, 183:101-116.
53. Song N., Boku S., Nakagawa S., Kato A., Toda H., Takamura N., et al. Mood stabilizers commonly restore staurosporine-induced increase of p53 expression and following decrease of Bcl-2 expression in SH-SY5Y cells. Prog. Neuropsychopharmacol. Biol. Psychiatry 2012, 38:183-189.